Erica Mann to lead Bayer’s Consumer Care division
LEVERKUSEN, Germany — Erica Mann has been named the new head of Bayer HealthCare’s Consumer Care division and member of the Bayer HealthCare executive committee. She will join the company March 14.
“Over the past 25 years, Mann has become noted in the industry for her strong record of delivering business results,” stated Jörg Reinhardt, Bayer chairman. “Her outstanding experience and insights will further enable [the consumer care division] to take advantage of the sustained growth forecast for the OTC market.”
Mann succeeds Gary Balkema, who has decided to retire. Mann most recently served as president and GM of Pfizer Nutritional Health, and was a member of the Pfizer senior management team.
Mann joined Pfizer upon its acquisition of Wyeth, where as SVP nutrition she helped establish the shape and strategic direction of the new nutrition business unit, and, as managing director, Wyeth Australia & New Zealand, introduced a range of significant medicines and nutritionals. She also led Wyeth’s Pharmaceutical business in South Africa for more than a decade as managing director and CEO.
Mann, born in Vereeniging, South Africa, holds an undergraduate degree in analytical chemistry and a marketing management diploma from the Institute of Marketing Management in Johannesburg, South Africa.
Welch promoted to VP scientific and regulatory affairs at NPA
WASHINGTON — The Natural Products Association on Wednesday announced the promotion of Cara Welch to VP scientific and regulatory affairs.
“Welch has been a major contributor to achieving the success of both our Natural Seal and GMP certification programs, and she is the perfect choice to lead this department,” stated John Gay, NPA executive director and CEO. “The NPA Natural Seal has been a huge success, with nearly 600 certifications since its launch in 2008.”
In her new role, Welch will oversee the NPA’s quality assurance programs, including good manufacturing practices certification and the NPA Natural Seal. She also will advise NPA members on regulatory, safety, nutrition and health issues, and will be responsible for assisting natural product industry members to implement policies in response to government initiatives in the regulatory arena and for working with officials in the Food and Drug Administration and other agencies whose actions have a direct impact on the natural products industry.
Prior to joining the NPA, Welch studied at the Department of Medicinal Chemistry at Rutgers University. Welch earned her M.S. in chemistry from the University of Iowa and her B.A. in chemistry from Dordt College. She is a member of the American Chemical Society and the American Society of Pharmacognosy, and serves as a peer-reviewer for editorial boards.
Amid counterfeit product warning, Biotab recalls two lots of Extenze
MONROVIA, Calif. — Biotab Nutraceuticals on Tuesday initiated a voluntary recall of two lots of Extenze nutritional supplement tablets.
Some packages bearing lot numbers 0709241 and 0509075 are counterfeit products containing undeclared drug ingredients that can pose a serious risk to health, the company stated.
Biotab learned about the problem after being notified by the Food and Drug Administration that lot 0709241 contains tadalafil and sildenafil, and lot 0509075 contains tadalafil and sibutramine. The counterfeit products are sold at retail nationwide in the form of carded four-packs (lot 0709241) and in the form of a box of thirty tablets divided into two 15-tablet blister packs (lot 0509075).
Tadalafil and sildenafil are drugs used to treat erectile dysfunction. These drugs may interact with nitrates found in some prescription drugs (such as nitroglycerin) and may lower blood pressure to dangerous levels. Consumers with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates.
Sibutramine is a controlled substance that was withdrawn from the market in October 2010 for safety reasons. Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke.
The counterfeit Extenze product is not manufactured, distributed or packaged by Biotab, but is falsely marked with the same lot numbers used by Biotab for its genuine product. Because it is very difficult to distinguish the counterfeit from the genuine product, Biotab decided to conduct this voluntary recall of the two affected lots. It is possible that there may be other counterfeit products on the market that have yet to be identified, the company cautioned.